RZLT Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -- compared to Rezolute, Inc.'s net margin of -39.02%. Rezolute, Inc.'s return on equity of -63.8% beat Geron Corp.'s return on equity of -29.65%.

Rezolute, Inc. has a consensus price target of $4.13, signalling upside risk potential of 50.55%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 157.14%. Given that Geron Corp. has higher upside potential than Rezolute, Inc., analysts believe Geron Corp. is more attractive than Rezolute, Inc..

Rezolute, Inc. has a beta of 0.211, which suggesting that the stock is 78.913% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.

Rezolute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rezolute, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Rezolute, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. Rezolute, Inc.'s net income of -$18.2M is higher than Geron Corp.'s net income of -$18.4M. Notably, Rezolute, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute, Inc. is -- versus 5.08x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Rezolute, Inc.'s net margin of 21.32%. Rezolute, Inc.'s return on equity of -63.8% beat Pfizer Inc.'s return on equity of 10.84%.

Rezolute, Inc. has a consensus price target of $4.13, signalling upside risk potential of 50.55%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Rezolute, Inc. has higher upside potential than Pfizer Inc., analysts believe Rezolute, Inc. is more attractive than Pfizer Inc..

Rezolute, Inc. has a beta of 0.211, which suggesting that the stock is 78.913% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Rezolute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Rezolute, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Rezolute, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Rezolute, Inc.'s net income of -$18.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Rezolute, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute, Inc. is -- versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -- compared to Rezolute, Inc.'s net margin of -45.06%. Rezolute, Inc.'s return on equity of -63.8% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Rezolute, Inc. has a consensus price target of $4.13, signalling upside risk potential of 50.55%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.61 which suggests that it could fall by -7.67%. Given that Rezolute, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Rezolute, Inc. is more attractive than Sarepta Therapeutics, Inc..

Rezolute, Inc. has a beta of 0.211, which suggesting that the stock is 78.913% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.348%.

Rezolute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rezolute, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Rezolute, Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Rezolute, Inc.'s net income of -$18.2M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Rezolute, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute, Inc. is -- versus 0.95x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -- compared to Rezolute, Inc.'s net margin of 52.48%. Rezolute, Inc.'s return on equity of -63.8% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Rezolute, Inc. has a consensus price target of $4.13, signalling upside risk potential of 50.55%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 148.17%. Given that XOMA Royalty Corp. has higher upside potential than Rezolute, Inc., analysts believe XOMA Royalty Corp. is more attractive than Rezolute, Inc..

Rezolute, Inc. has a beta of 0.211, which suggesting that the stock is 78.913% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.

Rezolute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Rezolute, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rezolute, Inc. quarterly revenues are --, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Rezolute, Inc.'s net income of -$18.2M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Rezolute, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute, Inc. is -- versus 9.04x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.